A-Mab Case Study

The is a landmark document in the biopharmaceutical industry, serving as a comprehensive template for applying Quality by Design (QbD) principles to the development of monoclonal antibodies (mAbs) . Published in 2009 by the CMC Biotech Working Group , it simulates the development of a hypothetical IgG1 monoclonal antibody to demonstrate how systematic, risk-based approaches can enhance process understanding and ensure product quality. Core Framework of the A-Mab Study

The case study explores optimization across the entire manufacturing lifecycle: A–Mab: A Case Study in Bioprocess Development - ISPE

Part 7: Economic and Timeline Outcomes

Enhanced Product Understanding

: Identifying which molecular attributes impact safety and efficacy.

The process begins with the host. For mAb-X, the goal was to maximize titer (the amount of antibody produced per liter of culture) while ensuring the protein remains stable.

Loading